UROGEN CORPORATE PRESENTATION JEFFERIES HEALTHCARE CONFERENCE June 2, 2020 2 FORWARD LOOKING STATEMENTS This investor presentation contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: the potential market opportunity of Jelmyto in LG-UTUC; commercial plans for favorable market access and physician uptake following the Jelmyto launch; plans for the successful launch of Jelmyto; the timing for completion of commerci ...

UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2020 Earnings Conference Call May 7, 2020 8:30 AM ET Company Participants Kate Bechtold - Senior Director, Investor Relations Liz Barrett - President & Chief Executive Officer Mark Schoenberg - Chief Medical Officer Jeff Bova - Senior Vice President, Commercial Peter Pfreundschuh - Chief Financial Officer Conference Call Participants Derek Archila - Stifel Nicolaus Paul Choi - Goldman Sachs Matthew Kaplan - Ladenburg Thalmann Boris Peaker - Cowen Leland Gershell - Oppenhe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38079 UROGEN PHARMA LTD. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or ...

UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2019 Earnings Conference Call March 2, 2020 8:30 AM ET Company Participants Kate Bechtold - Senior Director, Investor Relations Liz Barrett - President and Chief Executive Officer Mark Schoenberg - Chief Medical Officer Peter Pfreundschuh - Chief Financial Officer Jeff Bova - Senior Vice President, Commercial Conference Call Participants Derek Archila - Stifel Nicolaus Chris Howerton - Jefferies Paul Choi - Goldman Sachs Ram Selvaraju - H.C. Wainwright & Co. Matthew Kapla ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____________ to ________________ Commission file number: 001-38079 UROGEN PHARMA LTD. (Exact name of registrant as specified in its charter) Israel 98-1460746 (Sta ...

UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2019 Earnings Conference Call November 12, 2019 8:30 AM ET Company Participants Catherine Bechtold - Senior Director of IR Elizabeth Barrett - President and CEO Mark Schoenberg - Chief Medical Officer Peter Pfreundschuh - CFO Stephen Mullennix - COO Jeff Bova - SVP, Commercial Conference Call Participants Turner Kufe - JPMorgan Ram Selvaraju - H. C. Wainwright Boris Peaker - Cowen Leland Gershell - Oppenheimer Operator Good morning, ladies and gentlemen, thank you for sta ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38079 UROGEN PHARMA LTD. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation ...

UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2019 Earnings Conference Call August 12, 2019 8:30 AM ET Company Participants Catherine Bechtold - Director of Corporate Communications & IR Elizabeth Barrett - President, CEO Mark Schoenberg - Chief Medical Officer Peter Pfreundschuh - CFO & Secretary Stephen Mullennix - Chief Operating Officer Jeff Bova - Senior Vice President of Commercial Conference Call Participants Paul Choi - Goldman Sachs Boris Peaker - Cowen Ram Selvaraju - H.C. Wainwright Chris Howerton - Jeffer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION UROGEN PHARMA LTD. (Exact Name of Registrant as Specified in its Charter) WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____________ to ________________ Commission file number: 001-38079 (State or other juri ...

| --- | --- | |-----------------------------------------|-------| | | | | | | | | | | | | | Transforming Therapies in Uro-Oncology | | | June 2019 Corporate Presentation | | Forward-Looking Statements 2 This presentation and the accompanying oral presentation by UroGen Pharma Ltd. ("UroGen") contains forward-looking statements. All statements contained herein other than statements of historical fact constitute forward-looking statements, including statements regarding UroGen's anticipated results of operati ...